Gross revenue rose 10% YoY to R$15.5B, with EBITDA up 27.3% and net income up 13.9%. SulAmérica's full consolidation drove net revenue to R$8.7B (+7.9% YoY), while patient and surgical volumes, as well as oncology, showed strong growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.